BioMarin Pharmaceutical Inc.
BMRN
$58.14
$0.290.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 48.62% | 17.78% | -1.02% | 20.88% | 335.15% |
| Total Depreciation and Amortization | -6.52% | 24.21% | -28.18% | -3.24% | 1.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.51% | 109.70% | 10.16% | 43.20% | -53.02% |
| Change in Net Operating Assets | -8.79% | -312.87% | 158.37% | 36.50% | -8.52% |
| Cash from Operations | -6.05% | -16.19% | 86.49% | 152.84% | 70.91% |
| Capital Expenditure | 14.14% | -5.78% | 13.43% | 18.30% | 9.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -111.96% | 4,060.19% | -97.94% | 842.09% | 132.92% |
| Cash from Investing | -136.96% | 572.88% | -117.86% | 735.57% | 78.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -2,749,494.44% | -- | -- |
| Issuance of Common Stock | -- | 63.89% | -83.70% | 308.80% | -51.39% |
| Repurchase of Common Stock | -689.96% | 16.97% | 64.79% | 66.38% | -1,174.18% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 96.95% | -- | -- | 6.67% |
| Cash from Financing | -1,456.38% | 100.57% | -4,057.54% | 129.47% | -494.77% |
| Foreign Exchange rate Adjustments | -156.55% | 186.32% | -187.91% | 71.25% | 152.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -60.37% | 190.12% | -231.78% | 2,869.08% | 73.15% |